Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO
18 Settembre 2024 - 1:00PM
Oxford
Biomedica rebrands as OXB reinforcing transformation into leading
global cell and gene therapy CDMO
Oxford, UK – 18 September
2024: OXB (LSE:OXB), a quality and innovation-led
cell and gene therapy CDMO, today announces the launch of its new
corporate brand.
Oxford Biomedica is rebranding as OXB, unveiling
a more modern and recognisable visual identity that reinforces its
transformation into a global pure-play cell and gene therapy CDMO.
The new identity reflects OXB’s unique combination of technical
excellence, innovation and unwavering commitment to deliver
consistent high quality at every stage of viral vector development
and manufacturing. The new branding represents the agile execution
and creativity that enable OXB to deliver on clients’ goals, while
also conveying accountability, professionalism and teamwork – core
values that underpin OXB's mission.
Dr. Frank Mathias, Chief Executive
Officer of OXB, commented: “The launch of our new
brand identity reinforces OXB's significant transformation into a
leading pure-play cell and gene therapy CDMO. This rebranding is
more than just a new look – it reflects the global nature of our
operations and our deep commitment to the success of our clients’
drug development programmes. As OXB, with our new capabilities and
global footprint, we are ideally positioned to communicate our
end-to-end services to current and potential clients, and to
interact with them from early-stage development through to
commercial manufacturing.”
-Ends-
Enquiries:
OXB:
Sebastien Ribault, Chief Commercial
Officer – T: +44 (0) 1865 783 000 / E: partnering@oxb.com
ICR Consilium:T: +44
(0)20 3709 5700 / E: oxb@icrhealthcare.com
Mary-Jane Elliott / Angela Gray / Davide
Salvi
About OXB
OXB (LSE: OXB) is a
quality and innovation-led contract development and manufacturing
organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients
around the world.
One of the original
pioneers in cell and gene therapy, OXB has more than 25 years of
experience in viral vectors; the driving force behind the majority
of cell and gene therapies. OXB collaborates with some of the
world's most innovative pharmaceutical and biotechnology companies,
providing viral vector development and manufacturing expertise in
lentivirus, adeno-associated virus (AAV), adenovirus, and other
viral vector types. OXB's world-class capabilities span from
early-stage development to commercialisation. These capabilities
are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.
OXB offers a vast
number of unique technologies for viral vector manufacturing,
including a 4th generation lentiviral vector system (the
TetravectaTM system), dual plasmid system for AAV production,
suspension and perfusion process using process enhancers and stable
producer and packaging cell lines.
OXB, a FTSE4Good
constituent, is headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across Oxfordshire, UK,
Lyon and Strasbourg, France, and near Boston, MA, US. Learn more
at www.oxb.com, and follow us
on LinkedIn and YouTube.
Grafico Azioni Oxford Biomedica (LSE:OXB)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Oxford Biomedica (LSE:OXB)
Storico
Da Dic 2023 a Dic 2024
